Oral factor Xa inhibitors for stroke prevention in patients with device-detected atrial fibrillation – Recent evidence from the NOAH-AFNET 6 and ARTESiA trials

Alexander P. Benz; William F. McIntyre

doi:10.26430/CHUNGARICA.2024.54.2.90

Cardiologia Hungarica (Apr 2024)

Oral factor Xa inhibitors for stroke prevention in patients with device-detected atrial fibrillation – Recent evidence from the NOAH-AFNET 6 and ARTESiA trials

Alexander P. Benz,
William F. McIntyre

Affiliations

Alexander P. Benz: Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada, Department of Cardiology, University Medical Center Mainz, Johannes Gutenberg-University, Mainz, Germany
William F. McIntyre: Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada

DOI: https://doi.org/10.26430/CHUNGARICA.2024.54.2.90
Journal volume & issue: Vol. 54, no. 2
pp. 90 – 91

Abstract

Read online

Device-detected atrial fibrillation (AF), also known as atrial high rate episodes, is a frequent finding in patients with a cardiac implantable electronic device such as a pacemaker, or an implantable cardioverter-defibrillator or loop recorder.

Published in Cardiologia Hungarica

ISSN: 0133-5596 (Print); 1588-0230 (Online)
Publisher: Promenade Kft
Country of publisher: Hungary
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine
Website: https://cardiologia.hungarica.eu/

About the journal